Artificial intelligence accelerates the identification of nature-derived potent LOXL2 inhibitors.

The role of LOXL2 in cancer has been widely demonstrated, but current therapies targeting LOXL2 are not yet fully developed. We believe that selective nature-derived inhibition of LOXL2 may provide a better therapeutic approach for the treatment of cancer. Therefore, we adopted a comprehensive approach combining deep learning and traditional computer-aided drug design methods to screen LOXL2 selective inhibitors. Bioactivity and affinity of the potential LOXL2 inhibitors were determined by molecular docking and virtual screening. At the same time, we experimentally tested the effect of potential LOXL2 inhibitors on cancer cells. Validation showed that it could inhibit proliferation and migration, promote apoptosis of CT26 cells, and reduce the expression level of LOXL2 protein. As a result, we identified a potent LOXL2 inhibitor: the natural product Forsythoside A, and demonstrated that Forsythoside A has an inhibitory effect on tumors.